What Happens To Your Body When You Stop Taking Drugs Like Ozempic? Study Explains
"Significant weight regain occurred eight weeks after discontinuation of AOMs and was sustained through 20 weeks. Different weight regain was observed in subjects with different characteristics," author Han Wu said.
The study found that GLP-1 medications, in particular, showed significant weight regain after treatment discontinuation. Participants who used these medications regained an average of 2.5 kilograms (5.5 pounds) approximately 20 weeks after stopping treatment. Notably, the research also revealed a pattern where individuals who lost more weight during treatment tended to regain more weight afterwards, suggesting that the amount of weight lost is a predictor of subsequent weight regain.
To isolate the effects of stopping anti-obesity medications, researchers controlled for factors like exercise levels and diabetes status. However, the underlying reasons for weight regain after treatment stoppage remain unclear. Future studies may investigate these mechanisms further, but weight loss may alter the body's physiology in ways that make maintaining a healthy weight more challenging. This potential "rewiring" of the body could contribute to the difficulty in sustaining weight loss after stopping treatment.
Weight regain after treatment isn't just unique to weight-loss medications. It's also been observed with surgical treatments like gastric bypasses and vertical banded gastroplasty.
Rise Of Ozempic
Ozempic, a drug developed by Novo Nordisk, was approved in 2017 for type 2 diabetes management but has surged in popularity for its weight-loss side effects. Its active ingredient, semaglutide, enhances insulin production, slows digestion, and suppresses appetite, leading to significant weight loss. Its off-label use for obesity, amplified by social media and celebrity endorsements like Elon Musk and Oprah, transformed it into a cultural phenomenon, generating $21 billion in 2023 sales. The demand for Ozempic has surged, leading to shortages and increased costs.
Side effects like nausea, muscle loss, and severe gastrointestinal issues affect some users, with weight often returning post-treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
‘NASA is under attack': Massive NASA layoffs see 20% staff fired amid Donald Trump's fund cuts; nationwide protests erupt
Image: Nearly 20% of NASA's workforce — approximately 3,870 employees — have exited the agency following major funding cuts under the Trump administration's plan to downsize federal agencies. The layoffs stem from the Deferred Resignation Program, with officials describing the move as an effort to make NASA 'leaner and more efficient.' The decision has triggered widespread backlash from scientists, engineers, and space policy experts, who warn of serious risks to the agency's future missions. Nationwide protests erupted over the weekend, with current and former employees calling the move a direct threat to America's leadership in space. NASA fires thousands under federal downsizing drive The second round of the Deferred Resignation Program, which closed late Friday, saw roughly 3,000 resignations on top of 870 from the first wave of departures after Trump returned to office. Including regular attrition, NASA's workforce has shrunk from over 18,000 to around 14,000, marking a 20% reduction. Those resigning have been placed on administrative leave until their official exit. The move was orchestrated under the Department of Government Efficiency, currently led by Elon Musk. NASA insists that safety remains a top priority, yet internal experts are raising alarms about the loss of institutional knowledge and highly skilled personnel. With Mars and Moon missions central to the Trump administration's ambitions, critics argue these cuts threaten mission readiness. Former NASA officials and space industry leaders are questioning the agency's capacity to manage complex space programs in the coming years. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Live Comfortably: 60m2 prefabricated bungalow for the elderly in Tebas Pre Fabricated Homes | Search Ads Search Now Undo Protests erupt over 'brain drain' and loss of legacy Protests have broken out in several cities including Houston, Washington D.C., and Cape Canaveral, where current and former NASA staff, union representatives, and supporters gathered to oppose the mass layoffs. A letter titled The Voyager Declaration, signed by hundreds of former employees, warns that irreplaceable expertise is being lost at a critical moment for U.S. space exploration. 'This is not streamlining,' one protestor said, 'this is sabotage.' Doubts over leadership as Trump's NASA pick falters Adding to the turmoil, NASA is still being led by an acting administrator after tech billionaire Jared Isaacman, Trump's initial nominee backed by Elon Musk, was rejected for the role. In the absence of permanent leadership, critics argue that the agency is navigating its most challenging transformation without a clear long-term vision or stable command structure.
Time of India
2 hours ago
- Time of India
US lawmakers press FDA to target knockoff weight-loss drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market-a problem that emerged over the last year. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity MCA Data Science Degree Leadership PGDM Public Policy Operations Management others Others Product Management healthcare Digital Marketing MBA Technology Project Management CXO Finance Artificial Intelligence Healthcare Data Analytics Management Design Thinking Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details "We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications," they wrote in a letter to FDA commissioner Marty Makary. "Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo The group-spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey-asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the "urgency" of the situation. Live Events A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a "complete and thorough" response to the issues raised in the lawmakers' letter. "Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously," the spokesperson said. "And we are deeply committed to strengthening the oversight of imported products at US ports of entry." In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. "We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs," said a spokesperson for Hims & Hers Health, one of the telehealth firms that sells compounded GLP-1s. "We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first." Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.
Mint
5 hours ago
- Mint
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) More stories like this are available on
